[go: up one dir, main page]

AR121905A1 - Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv - Google Patents

Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv

Info

Publication number
AR121905A1
AR121905A1 ARP210101072A ARP210101072A AR121905A1 AR 121905 A1 AR121905 A1 AR 121905A1 AR P210101072 A ARP210101072 A AR P210101072A AR P210101072 A ARP210101072 A AR P210101072A AR 121905 A1 AR121905 A1 AR 121905A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
haloalkyl
independently selected
occurrence
Prior art date
Application number
ARP210101072A
Other languages
English (en)
Inventor
Thilo Heckrodt
Michael Walker
Min Zhong
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of AR121905A1 publication Critical patent/AR121905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Thin Film Transistor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona, en parte, compuestos de carboxamida de heteroarilo de 5 miembros, y composiciones farmacéuticas de estos, útiles para la interrupción del ensamblaje de la proteína del núcleo de HBV y métodos de tratamiento de la infección de la hepatitis B (HBV). Reivindicación 1: En un aspecto, la presente divulgación proporciona un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este, caracterizado porque: L es alquilenoC₁₋₄ o haloalquilenoC₁₋₄; L¹ y L² son independientemente un enlace, alquilenoC₁₋₆, O, NRᶜ, C(O), C(O)O, C(O)NRᶜ, S(O)ₜ o S(O)ₜNRᶜ; X¹ es NRˣ¹; X³ es CR⁴R⁸; X⁴ y X⁶ son independientemente O ó S; X⁵ es O, S o NR⁰; Rᵃ, Rᵇ y Rᶜ se seleccionan independientemente para cada aparición del grupo que consiste en hidrógeno, alquiloC₁₋₆, haloalquiloC₁₋₆ y monocicloalquiloC₃₋₆; Rᵈ es hidrógeno, OH, alquiloC₁₋₆ o alcoxiC₁₋₆; Rˣ¹ es hidrógeno, alquiloC₁₋₄, alqueniloC₁₋₄, alquiniloC₁₋₄, haloalquiloC₁₋₄ o monocicloalquiloC₃₋₆; o Rˣ¹ y R² juntos forman un grupo -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH₂CH₂O-, -CH₂OCH₂-, -CH₂CH₂CH₂O-, -CH₂CH₂OCH₂-, -CH₂CH₂-NH-, -CH₂NHCH₂-, -CH₂CH₂CH₂NH- o -CH₂CH₂NHCH₂-; R⁰ᵃ se selecciona independientemente para cada aparición del grupo que consiste en hidrógeno, halógeno, OH, CN, NO₂, RᵃRᵇN-, alquiloC₁₋₄ y haloalquiloC₁₋₄; R⁴ᵃ y R⁶ᵃ son independientemente hidrógeno o alquiloC₁₋₄; R⁰, R⁶ y R¹¹ se seleccionan independientemente para cada aparición del grupo que consiste en hidrógeno, halógeno, OH, CN, NO₂, oxo, RᵈN=, hidrazino, formilo, azido, sililo, siloxi, HOC(O)-, RᵃRᵇN-, RᵃRᵇNS(O)ₜ-, alquiloC₁₋₆, alqueniloC₂₋₆, alquiniloC₂₋₆, haloalquiloC₁₋₆, hidroxialquiloC₁₋₆-, RᵃRᵇNalquiloC₁₋₆-, HOC(O)alquiloC₁₋₆-, RᵃRᵇNalquiloC₁₋₆NRᶜ-, alquiloC₁₋₆NRᵃalquilo C₁₋₆NRᶜ-, alcoxiC₁₋₆, haloalcoxiC₁₋₆, hidroxialcoxiC₁₋₆-, RᵃRᵇNalcoxiC₁₋₆-, alcoxiC₁₋₆alquiloC₁₋₆-, haloalcoxiC₁₋₆alquiloC₁₋₆-, RᵃRᵇNC(O)-, alquiloC₁₋₆C(O)-, alcoxiC₁₋₆C(O)-, alquiloC₁₋₆C(O)O-, alquiloC₁₋₆S(O)q-, alquiloC₁₋₆S(O)ₜNRᶜ-, alquiloC₁₋₆S(O)ₜalquiloC₁₋₆-, alquiloC₁₋₆S(O)ₜNRᵃalquiloC₁₋₆-, cicloalquiloC₃₋₆S(O)ₜalquiloC₁₋₆-, alquiloC₁₋₆C(O)alquiloC₁₋₆- y alquiloC₁₋₆C(O)OalquiloC₁₋₆-; R¹ es un fenilo o heteroarilo monocíclico de 5 - 6 miembros, donde el fenilo o heteroarilo monocíclico de 5 - 6 miembros está opcionalmente sustituido con uno, dos o tres grupos R¹¹ seleccionados independientemente; R² y R⁸ se seleccionan independientemente del grupo que consiste en hidrógeno, halo, CN, OH, RᵃRᵇN, alquiloC₁₋₄, haloalquiloC₁₋₄, monocicloalquiloC₃₋₅, alcoxiC₁₋₄ y haloalcoxiC₁₋₄; R³ es un resto de fórmula (2); R⁴ es R⁵-L¹-, R⁶ o R⁹; R⁵ es un resto de fórmula (3); R⁹ es R¹⁴S(O)q-L-, R¹⁴S(O)qNH-L-, o R¹⁴C(O)NH-L-; R¹⁴ es RᵃRᵇN-, alquiloC₁₋₆, alqueniloC₂₋₆, alquiniloC₂₋₆, haloalquiloC₁₋₆, alcoxiC₁₋₆, haloalquiloC₁₋₆, haloalcoxiC₁₋₆, o R⁵-L¹-; q, r, t, y w se seleccionan independientemente para cada aparición entre 0, 1 y 2; y v se selecciona independientemente para cada aparición entre 0, 1, 2 y 3.
ARP210101072A 2020-04-22 2021-04-21 Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv AR121905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063014001P 2020-04-22 2020-04-22

Publications (1)

Publication Number Publication Date
AR121905A1 true AR121905A1 (es) 2022-07-20

Family

ID=75919388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101072A AR121905A1 (es) 2020-04-22 2021-04-21 Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv

Country Status (14)

Country Link
US (1) US20230183213A1 (es)
EP (1) EP4139292A1 (es)
JP (2) JP2023523241A (es)
KR (1) KR20230005881A (es)
CN (2) CN115843294A (es)
AR (1) AR121905A1 (es)
AU (1) AU2021261307A1 (es)
BR (1) BR112022021419A2 (es)
CA (1) CA3180706A1 (es)
IL (1) IL297305A (es)
MX (1) MX2022013251A (es)
PH (1) PH12022552815A1 (es)
TW (1) TW202206415A (es)
WO (1) WO2021216656A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023067518A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. Process
WO2023069547A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US20250250257A1 (en) * 2021-10-20 2025-08-07 Assembly Biosciences, Inc. Novel crystalline forms
WO2023069545A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
EP4448492A1 (en) 2021-12-17 2024-10-23 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
AU2024229823A1 (en) 2023-02-28 2025-09-11 Reglagene, Inc. Compositions and methods for making and using small molecules for the treatment of health conditions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
WO2013010069A1 (en) 2011-07-13 2013-01-17 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
AR089671A1 (es) 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
AU2013307328B2 (en) 2012-08-28 2017-10-19 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112015004113A2 (pt) 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
KR20150093685A (ko) 2012-11-09 2015-08-18 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 Hbv 어셈블리 이펙터의 대체 용도
CA2892606A1 (en) 2012-12-06 2014-06-12 Baruch S. Blumberg Institute Functionalized benzamide derivatives as antiviral agents against hbv infection
EA201591220A1 (ru) 2012-12-27 2016-01-29 Дрексел Юниверсити Новые противовирусные агенты против инфекции вирусом гепатита в
MX366123B (es) 2013-02-28 2019-06-27 Janssen Sciences Ireland Uc Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
PL3024819T3 (pl) * 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
SG10202001506UA (en) * 2014-03-13 2020-04-29 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
TW201720802A (zh) * 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
SG11201807543YA (en) * 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
WO2018005881A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
US10987360B2 (en) * 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
WO2019076358A1 (en) * 2017-10-19 2019-04-25 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
JP2022508953A (ja) * 2018-10-22 2022-01-19 アッセンブリー バイオサイエンシズ，インコーポレイテッド Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物
WO2021216660A1 (en) * 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv

Also Published As

Publication number Publication date
WO2021216656A1 (en) 2021-10-28
CN115843294A (zh) 2023-03-24
CN121248511A (zh) 2026-01-02
KR20230005881A (ko) 2023-01-10
US20230183213A1 (en) 2023-06-15
MX2022013251A (es) 2022-11-14
IL297305A (en) 2022-12-01
EP4139292A1 (en) 2023-03-01
JP2025186437A (ja) 2025-12-23
JP2023523241A (ja) 2023-06-02
CA3180706A1 (en) 2021-10-28
PH12022552815A1 (en) 2024-03-25
TW202206415A (zh) 2022-02-16
BR112022021419A2 (pt) 2023-03-07
AU2021261307A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
AR121905A1 (es) Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv
PE20241341A1 (es) Compuestos terapeuticos para la infeccion por el virus vih
AR120684A1 (es) INHIBIDORES DE HIF-2a
AR117616A1 (es) Compuestos anti-vih
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR124369A1 (es) Inhibidores de prmt5 novedosos
AR114972A1 (es) Compuestos
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
BRPI0518424B8 (pt) derivados de 2,4 (4,6) pirimidina, composição farmacêutica que os compreende, intermediários e uso dos mesmos
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR117424A1 (es) Inhibidores de los receptores erbb
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR124048A1 (es) Inhibidores de la btk
AR037770A1 (es) Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR127483A1 (es) Compuestos antibacterianos
AR111658A1 (es) 2-quinolinonas tricíclicas como agentes antibacteriales
AR129089A1 (es) Inhibidores de kit
AR119378A1 (es) Formulación de nanopartículas del inhibidor de bcl-2
AR116800A1 (es) Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento del vhb
AR123803A1 (es) Compuestos fosfolípidos y usos de estos
AR129371A1 (es) Compuestos amido-heteroaromáticos
AR120088A1 (es) Derivados de naftiridina y quinolina como inhibidores de la proteína cinasa